Crisaborole is a topical nonsteroidal antiinflammatory PDE4 inhibitor that has completed phase 3 clinical studies for the treatment of children, adolescents, and adults with mild to moderate AD 8, 9. The gene discussed is PDE4A; the disease is Alzheimer disease.